Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA
Authors:
Open Access
- 18 May 2018
- journal article
- review article
- Published by SAGE Publications in Tumor Biology
- Vol. 40 (5)
Abstract
Biomarkers are the key to personalized treatment in patients with breast cancer. While tissue biomarkers are most useful in determining prognosis and upfront predicting response to therapy, circulating protein biomarkers such as CA 15-3 and carcinoembryonic antigen are mainly used in monitoring response to endocrine or chemotherapy in patients with advanced disease. Although several centers measure biomarkers in asymptomatic patients following curative surgery for primary breast cancer, the clinical utility of this practice is unclear. Promising new biomarkers for breast cancer include circulating tumor DNA and circulating tumor cells. In contrast to circulating protein biomarkers, measurement of circulating tumor DNA–based biomarkers is potentially useful in identifying mechanisms of resistance to ongoing therapies as well as identifying new targets for further treatment. To increase clinical utility, both the established and emerging circulating biomarkers should where possible be incorporated into randomized trials evaluating new therapies in patients with breast cancer.Keywords
Funding Information
- Irish Cancer Society, Breast Predict Programme (CCRC13GAL)
This publication has 83 references indexed in Scilit:
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerNew England Journal of Medicine, 2013
- Circulating tumour cells in non-metastatic breast cancer: a prospective studyThe Lancet Oncology, 2012
- Vimentin in cancer and its potential as a molecular target for cancer therapyCellular and Molecular Life Sciences, 2011
- Detection of HER2 amplification in circulating free DNA in patients with breast cancerBritish Journal of Cancer, 2011
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPAEuropean Journal of Cancer, 2004
- Ca 15-3 in the follow-up of localised breast cancerEuropean Journal of Cancer, 2002
- The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markersEuropean Journal of Cancer, 1999